Recently, the lifetime ban on Martin Shkreli, the notorious former pharmaceutical executive, has been upheld by a federal appeals court. What Happened: The 2nd U.S. Circuit Court of Appeals in Manhattan upheld the decision on Tuesday, Reuters reported. The ban was imposed due to Shkreli’s antitrust violations, leading to a $64.6 million repayment order. The ban was initially imposed in January 2022 by U.S. District Judge Denise Cote, who cited Shkreli’s “particularly heartless and coercive” tactics in monopolizing the antiparasitic drug Daraprim and preventing generic rivals from entering the …

Read More